325 related articles for article (PubMed ID: 2873133)
1. Mesoridazine and thioridazine: clinical effects and blood levels in refractory schizophrenics.
Vital-Herne J; Gerbino L; Kay SR; Katz IR; Opler LA
J Clin Psychiatry; 1986 Jul; 47(7):375-9. PubMed ID: 2873133
[TBL] [Abstract][Full Text] [Related]
2. Absorption and excretion of thioridazine and mesoridazine in man.
Charalampous KD; Johnson PC; Estevez V
Dis Nerv Syst; 1974 Nov; 35(11):494-6. PubMed ID: 17896456
[TBL] [Abstract][Full Text] [Related]
3. Isolation of a possible new metabolite of thioridazine and mesoridazine from human plasma.
Dinovo EC; Gottschalk LA; Noble EP; Biener R
Res Commun Chem Pathol Pharmacol; 1974 Mar; 7(3):489-96. PubMed ID: 4824823
[No Abstract] [Full Text] [Related]
4. A clinical study of mesoridazine and chlorpromazine in relapsed schizophrenic patients.
Bankier RG; Mathewson FA
Dis Nerv Syst; 1972 Aug; 33(8):529-34. PubMed ID: 4567534
[No Abstract] [Full Text] [Related]
5. Blood levels of haloperidol and thioridazine during maintenance neuroleptic treatment of schizophrenic outpatients.
Shvartsburd A; Sajadi C; Morton V; Mirabi M; Gordon J; Smith RC
J Clin Psychopharmacol; 1984 Aug; 4(4):194-8. PubMed ID: 6470190
[TBL] [Abstract][Full Text] [Related]
6. An open study of mesoridazine (Serentil) in chronic schizophrenics.
Aguilar SJ
Dis Nerv Syst; 1975 Sep; 36(9):484-9. PubMed ID: 1175465
[TBL] [Abstract][Full Text] [Related]
7. A double-blind comparison of mesoridazine and chlorpromazine in chronic schizophrenics.
Freeman H
Dis Nerv Syst; 1973; 34(6):289-93. PubMed ID: 4782285
[No Abstract] [Full Text] [Related]
8. Mesoridazine versus chlorpromazine in acute schizophrenia: a double-blind investigation.
Hamid TA; Wertz WJ
Am J Psychiatry; 1973 Jun; 130(6):689-92. PubMed ID: 4573820
[No Abstract] [Full Text] [Related]
9. Treatment with mesoridazine and thioridazine in chronic schizophrenia: I. Assessment of clinical and electrophysiologic responses in refractory hallucinating schizophrenics.
Gardos G; Tecce JJ; Hartmann E; Bowers P; Cole JO
Compr Psychiatry; 1978; 19(6):517-25. PubMed ID: 720036
[No Abstract] [Full Text] [Related]
10. Early phase II clinical trial of remoxipride in treatment of schizophrenia with measurements of prolactin and neuroleptic activity.
Chouinard G
J Clin Psychopharmacol; 1987 Jun; 7(3):159-64. PubMed ID: 2885345
[TBL] [Abstract][Full Text] [Related]
11. Plasma and red cell levels of thioridazine and clinical response in schizophrenia.
Smith RC; Baumgartner R; Ravichandran GK; Shvartsburd A; Schoolar JC; Allen P; Johnson R
Psychiatry Res; 1984 Aug; 12(4):287-96. PubMed ID: 6594712
[TBL] [Abstract][Full Text] [Related]
12. Plasma levels of mesoridazine and its metabolites and clinical response in acute schizophrenia after a single intramuscular drug dose.
Gottschalk LA; Dinovo E; Bierner R
Psychopharmacol Bull; 1975 Oct; 11(4):33-4. PubMed ID: 812135
[No Abstract] [Full Text] [Related]
13. Comparison of the effects of thioridazine and mesoridazine on the QT interval in healthy adults after single oral doses.
Salih IS; Thanacoody RH; McKay GA; Thomas SH
Clin Pharmacol Ther; 2007 Nov; 82(5):548-54. PubMed ID: 17410120
[TBL] [Abstract][Full Text] [Related]
14. Greater potency of mesoridazine and sulforidazine compared with the parent compound, thioridazine, on striatal dopamine autoreceptors.
Niedzwiecki DM; Mailman RB; Cubeddu LX
J Pharmacol Exp Ther; 1984 Mar; 228(3):636-9. PubMed ID: 6707914
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetic interaction of fluvoxamine and thioridazine in schizophrenic patients.
Carrillo JA; Ramos SI; Herraiz AG; Llerena A; Agundez JA; Berecz R; Duran M; Benítez J
J Clin Psychopharmacol; 1999 Dec; 19(6):494-9. PubMed ID: 10587283
[TBL] [Abstract][Full Text] [Related]
16. Pimozide treatment of the negative schizophrenic syndrome: an open trial.
Feinberg SS; Kay SR; Elijovich LR; Fiszbein A; Opler LA
J Clin Psychiatry; 1988 Jun; 49(6):235-8. PubMed ID: 3288615
[TBL] [Abstract][Full Text] [Related]
17. Partitioning of thioridazine and mesoridazine in human blood fractions.
Dinovo EC; Pollak H; Gottschalk LA
Methods Find Exp Clin Pharmacol; 1984 Mar; 6(3):143-6. PubMed ID: 6748818
[TBL] [Abstract][Full Text] [Related]
18. Relevance of CYP2D6 -1584C>G polymorphism for thioridazine:mesoridazine plasma concentration ratio in psychiatric patients.
Dorado P; Peñas-LLedó EM; de la Rubia A; LLerena A
Pharmacogenomics; 2009 Jul; 10(7):1083-9. PubMed ID: 19604081
[TBL] [Abstract][Full Text] [Related]
19. Thioridazine improves affective symptoms in schizophrenic patients.
Dufresne RL; Valentino D; Kass DJ
Psychopharmacol Bull; 1993; 29(2):249-55. PubMed ID: 8290673
[TBL] [Abstract][Full Text] [Related]
20. Comparative study of two antipsychotic drugs in a state hospital.
Palestine ML
Dis Nerv Syst; 1972 Jun; 33(6):395-402. PubMed ID: 4668959
[No Abstract] [Full Text] [Related]
[Next] [New Search]
